贝伐单抗
Bevacizumab.
作者信息
Ellis Lee M
机构信息
University of Texas MD Anderson Cancer Center, Houston 77230-1402, USA.
出版信息
Nat Rev Drug Discov. 2005 May;Suppl:S8-9. doi: 10.1038/nrd1727.
DOI:10.1038/nrd1727
PMID:15962523
Abstract
Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular endothelial growth factor, was approved by the US FDA in February 2004 for the first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy. It is the first approved agent to target tumour angiogenesis.
摘要
贝伐单抗（阿瓦斯汀；基因泰克/罗氏公司）是一种抗血管内皮生长因子的抗体，于2004年2月获美国食品药品监督管理局批准，与基于5-氟尿嘧啶的化疗联合用于转移性结直肠癌的一线治疗。它是首个获批的靶向肿瘤血管生成的药物。
Zotero 插件